There are comments on PubPeer for publication: Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis (2011)
The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports interleukin 2- and interleukin 4-independent growth of helper T cells especially from murine and human sources and further which is capable of augmenting proliferation of IL3- or IL4-responsive cells. Even more particularly, the present invention relates to the helper T cell growth factor P40, pharmaceutical compositions thereof, antibodies thereto and recombinant DNA clones thereof. The present invention also contemplates a method for inducing the proliferation of helper T cells as well as IL3- and Il4-responsive cells. The helper T cells growth factor contemplated herein is useful in the stimulation of specific cells in the immune system, either alone or in combination with IL3 or IL4.
Rabbit anti Mouse Interleukin-22 antibody recognizes mouse interleukin-22 (IL-22), a regulatory cytokine and member of the IL-10 family, s
Results Most patients showed good clinical responses after low-dose IL-2 treatment (7 out of 9). Clinical improvement was observed with SIR-4 response (6 out of 9), improved complement 3 and 4 serum level (9 out of 9) and decreased anti-ds-DNA serum level (8 out of 9). Functional profiling of CD8 T cells in low-dose IL-2 treated patients revealed increased frequencies of CEF viral peptide specific TNF-a+ and Granzyme-B+ CD8 T cells. Moreover, these patients showed stronger antigen-specific response demonstrated by an increased stimulated/non-stimulate TNF-a-producing CD8 T cells proliferation fold. Compared with HC, SLE patients showed significantly lower frequencies of CEF specific Granzyme-B producing CD8 T cell, and low-dose IL-2 significantly increased the frequency of these Granzyme-B+ CD8 T cells in SLE patients. ...
This study will see how safe and useful infusion of tumor infiltrating lymphocytes and interleukin-2 therapy following a preparative regimenregimen is in
After the screening procedures confirm that you are eligible to participate in the research study: If you take part in this research study, you (and your donor) will have the following tests and procedures:. Donor Lymphocytes Collection: Lymphocytes are a type of white blood cell involved with the immune system. Your original marrow/stem cell donor will undergo one white blood cell collection procedures called leukapheresis. Blood from the vein in one arm will be circulated through a special machine to remove the white blood cells, and the rest of the blood will be returned to the donors other arm. The cells collected from the leukapheresis will be sent to the laboratory where the amount of white blood cells collected will be measured. A sample will be removed for study testing, and the remaining lymphocytes will be set-aside for infusion.. Donor Lymphocyte Processing: Once the lymphocytes are collected from your donor, the CliniMACS System device will enrich (preferentially select) the number ...
CD4+CD25+Foxp3+Treg is a functionally distinct subset of mature T cells with broad suppressive activity and has been shown to play an important role in the establishment of immune tolerance after...
PRIMARY OBJECTIVES:. I. Determine clinical response rates in patients with advanced melanoma treated with gp100:209-217(210M) melanoma vaccine and low-dose interleukin-2.. II. Assess response duration and progression-free intervals in these patients receiving this treatment.. OUTLINE:. Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 subcutaneously (SC) on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a complete response (CR) receive 3 additional courses after achieving CR.. Patients are followed every 9 weeks for 3 years or until disease recurrence.. PROJECTED ACCRUAL: A total of 25-50 patients will be accrued for this study within 3.5 years. ...
IL-15 is important for the development and normal function of NK cells, NKT cells, and memory CD8+ T cells. In this study, we investigated the importance of the cytoplasmic domain of IL-15Rα by replacing it with that from IL-2Rα. Although the chimeric construct had similar mRNA expression to that observed for WT IL-15Rα, its cell-surface expression was diminished, ostensibly due to increased intracellular "trapping" of the chimeric receptor. Like IL-15Rα, IL-2Rα also recycles to the cell surface; thus, these results indicate that the IL-15Rα cytoplasmic domain is more efficient for this process than is the IL-2Rα cytoplasmic domain. In addition to the importance of the IL-15Rα cytoplasmic domain for cell-surface expression, it is also needed for normal signaling, given defective proliferation to submaximal concentrations of IL-15 in 32D-IL-2Rβ transfectants in which similar levels of WT and the KI constructs were expressed.. IL-15Rαext/IL-2Rαint KI mice had reduced numbers of thymic ...
产品名称:Anti-Mouse/RatIL-17APEeBio17B7规格:50ug货号:12-7177-81厂商:eBioscience产品介绍:Alsoknownas:Interleukin-17A,CytotoxicT-lymphocyte-associatedantigen8,CTLA-8Clone:eBio17B7HostRatIsotypeIgG2a,kappaReactivityMo
产品名称:Anti-Mouse/RatIL-17APerCP-Cy5.5eBio17B7规格:100ug货号:45-7177-82厂商:eBioscience产品介绍:Alsoknownas:Interleukin-17A,CytotoxicT-lymphocyte-associatedantigen8,CTLA-8Clone:eBio17B7HostRatIsotypeIgG2a,kappaRe
For each of the following parametric tests, identify the appropriate non-parametric counterpart: a. Dependent t test b. Independent samples t tes...
He, Jing,Zhang, Xia,Sun, Xiaolin,et al. Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus[J]. ARTHRITIS & RHEUMATOLOGY,2014,suppl.10(SI):S290-S290 ...
Low-dose interleukin-2 and retinoic acid give unexpected 5-year survival rates for patients with advanced cancers. In a clinical trial of 500 patients with different types of stage 4 solid tumors who had responded to chemotherapy, a maintenance regimen with low-dose interleukin-2 (IL-2) and 13-cis retinoic acid (RA) has shown unexpected 5-year survival rates.. Francesco Recchia, MD, director of oncology at the Civilian Hospital in Avezzano, Italy, is scheduled to present findings from this extended phase II study in a presentation at the American Association for Cancer Research Annual Meeting 2012 in Chicago on April 2.. The open, nonrandomized trial showed substantial improvements for these patients with metastatic cancer compared with corresponding U.S. National Cancer Institute Surveillance Epidemiology and End Results (SEER) data for 5-year overall survival (OS) rates. The OS rate was 42.7% for patients in the study versus 23.3% for breast cancer patients accounted for in SEER data, and ...
TY - JOUR. T1 - Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. AU - Agarwala, S. S.. AU - Glaspy, J.. AU - ODay, S. J.. AU - Mitchell, M.. AU - Gutheil, J.. AU - Whitman, E.. AU - Gonzalez, R.. AU - Hersh, E.. AU - Feun, L.. AU - Belt, R.. AU - Meyskens, F.. AU - Hellstrand, K.. AU - Wood, D.. AU - Kirkwood, J. M.. AU - Gehlsen, K. R.. AU - Naredi, P.. PY - 2002/1/1. Y1 - 2002/1/1. N2 - Purpose: Reactive oxidative species (ROS) produced by phagocytic cells have been ascribed a role in the localized suppression of lymphocyte function within malignant tumors. Histamine has been shown to inhibit ROS formation and possibly synergize with cytokines to permit activation of natural killer cells and T cells. This study was designed to determine whether the addition of histamine to a subcutaneous (SC) regimen of interleukin-2 (IL-2) would improve the survival of ...
A retrospective analysis of High-Dose Interleukin-2 HD IL-2 following Ipilimumab in metastatic melanoma. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
IL-2 deficiency and associated regulatory T cell (Treg) defects critically contribute to SLE pathogenesis. In our previous translational work we proved the efficacy and safety of a low-dose IL-2 therapy in animal models and identified a reversible IL-2 deprivation of Treg also in human SLE patients. Together, these studies provided the rationales for an IL-2-based immunotherapy of SLE in order to restore Treg activity and thus to re-establish endogenous mechanisms of tolerance that can counteract autoimmunity.. Here we report that a cyclic and subcutaneously applied low-dose IL-2-therapy induced a rapid, strong and sustained reduction of disease activity in parallel to a remarkable and selective expansion of the Treg population in a SLE patient with increased disease activity (SELENA-SLEDAI 14) refractory to a large variety of approved and experimental therapies. Already after the first therapeutic cycle, signs of arthritis and later also myositis and active skin eruptions disappeared. In ...
Researchers evaluated the safety and efficacy of low-dose IL-2 therapy in systemic lupus erythematosus in a double-blind and placebo-controlled trial.
Adoptive immunotherapy for stage IV renal cell carcinoma: A novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2. The American Journal of Medicine. 1987 ...
Interleukin-5 (IL-5) is a hematopoietic growth factor expressed in Th2, mast cells and eosinophils. IL-5 acts through its receptor, the IL-5 receptor (IL-5R) and is involved in B-cell growth and eosinophil activation. IL-5 has been shown to be and is regulated by GATA-3, in addition to other transcription factors. Human and mouse IL-5 are cross-reactive. Recombinant mouse IL-5 is a non-glycosylated, disulfide-linked homodimer. It is comprised of two 113 amino acid chains with a total molecular weight of 26.2 kDa. Ships ambient. Store frozen at -20 to -10C. ...
Signaling mediated through the IL-2R, in conjunction with signals mediated through the T cell Ag receptor, promotes the proliferation and effector function of T cells (32). Some of the signals, such as up-regulation of the IL-2R α-chain, result from cooperative signals mediated both through the T cell Ag receptor as well as through the IL-2R itself; however, the relative role of signals delivered through these pathways has not been fully elucidated. Human tumor-reactive effector T cells have been shown to proliferate extensively in vitro in the presence of high-dose IL-2 alone (33). In addition, between 15 and 20% of melanoma and renal cancer patients treated with high-dose IL-2 alone respond to therapy (6), which may reflect the ability of IL-2 to maintain the proliferation of T cells that were activated by prior exposure to tumor Ags.. Interactions between the costimulatory receptor CD27 and its ligand, CD70, have also been found to play a key role in T lymphocyte activation, proliferation, ...
|p|Recombinant Mouse IL-11 is a a single non-glycosylated polypeptide chain containing 179 amino acids.|/p| |p|Background: Interleukin 11 is a pleiotropic cytokine that was originally detected in the conditioned medium of an IL-1α-stimulated primat
Mouse interleukin-12p70 (IL-12p70) is a disulfide-linked heterodimer consisting of IL-12a (p35 subunit) and IL-12b (p40 subunit) that is mainly produced by macrophages and T lymphocytes. The IL-12a subunit also dimerizes with Ebi3 to form IL-35, and the IL-12b subunit dimerizes with IL-23a to form IL-23. IL-12, IL-23, IL-27, and IL-35 are all heterodimeric proteins and members of IL-12 cytokine family. IL-12p70 activates T cells and natural killer cells that stimulate the production of IFN-γ. It is involved in a number of disorders including peritonitis and chronic toxoplasmosis.The Mouse IL-12p70 Kit provides assay-specific components for the quantitative determination of endogenous IL-12p70 in mouse urine, serum, plasma, and cell culture supernatants. ...
Sustained persistence and function of adoptively transferred T-cells are critical parameters for effective anti-tumor activity. To address this, our group has explored the mechanisms by which TLR agonist-induced cytokines, such as IL-12, are capable of efficiently priming CD8+ T-cells. IL-12 primed CD8+ T-cells upregulate the expression of the high affinity IL-2 receptor (CD25) and STAT5. Enhancement of these signaling components increases IL-2 mediated signaling events at low concentrations of IL-2. Blockade with anti-CD25 antibody effectively terminates this enhanced IL-2 signaling in IL-12 primed CD8+ T-cells. More importantly, IL-12 priming of CD8+ T-cells significantly increases in vivo proliferation as measured by CFSE dilution, and ex vivo recovery from lymphoid organs. Utilization of in vivo bioluminescent imaging of firefly luciferase transduced IL-12 primed T-cells demonstrated their ability to traffic into the tumor area, through lymph nodes and bone marrow. Finally, adoptive transfer ...
The R2-9A5 monoclonal antibody reacts with mouse interleukin-12 (IL-12), a heterodimeric 75 kDa (p75) cytokine consisting of two covalently linked subunits, 40 kDa (p40) and 35 kDa (p35). IL-12 is secreted by activated monocytes, macrophages, dendritic cells and T cells in response to bacterial pathogens or products such as lipopolysaccharides (LPS). IL-12 is a potent regulator of cell-mediated immune responses and plays a key role in the development of Th1 responses, leading to IFNγ and IL-2 production. The R2-9A5 antibody has been shown to neutralize the biological effects of IL-12 when administered |em|in vivo|/em|.
This phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors. Monoclonal
Recombinant Mouse Interleukin-6 produced inE.Coliis a single, non-glycosylated polypeptide chain containing 187 amino acids and having a molecular mass of 21709 Dalton. The IL-6 is purified by proprietary chromatographic techniques.
Rabbit anti Rat Interleukin-2 antibody specifically recognizes rat interleukin-2 (IL-2), otherwise known as T-cell growth factor, a multi-
AlphaLISA no-wash assay kit for detection and quantitation of Mouse Interleukin-1ß (IL-1ß) in serum, buffered solution or cell culture medium.
Combining high-dose interleukin-2 and personalized vaccines to activate patients immune systems improves survival of metastatic melanoma even more than IL-2 alone.
Interleukin-2 (IL-2), originally known as T cell growth factor (TCGF), is a cytokine that plays a critical role in promoting and controlling T cell response and function.
Mollereau C et. al. (1993) The high-affinity interleukin 8 receptor gene (IL8RA) maps to the 2q33-q36 region of the human genome: cloning of a pseudogene (IL8RBP) for the low-affinity receptor.. [^] ...
Interleukin 2 (IL-2) is a monomeric glycoprotein that is primarily produced by activated CD4+ T cells, CD8+ T cells and dendritic cells. It is characterized as a proinfla..
Rat IL-10 also known as TGIF, MCSF III, CSIF & B TCGF is a pleiotropic cytokine playing an important role as a regulator of lymphoid & myeloid cell function
Gentaur molecular products has all kinds of products like :search , FabGennix \ Interleukin 32 or NK4, WB control \ PC-IL32 for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , Accu \ Interleukin_4, Rat anti_Mouse \ ACLANT108B for more molecular products just contact us
白血球介素或介白素(interleukin(是一組細胞因子(分泌的信號分子(》最早發現在白血球中表達作為細胞間信號傳遞的手段》實際上3白血球介素可以由多種細胞產生》免疫系統的功能3在很大程度上依賴於白細胞介素》一些罕見的白細胞介素缺陷不足都常出現自身免疫性疾病或免疫缺陷》 ...
interleukin 7 recombinant human interleukin 7 | order interleukin 7 recombinant human interleukin 7 | How to use: interleukin 7 recombinant human interleukin 7 | suppo
A simple in vitro experimental system was devised to reflect the in vivo generation of a T cell anamnestic response so that T cell differentiation could be examined at the level of lymphokine gene expression. Comparison of neonatal and adult T cells revealed that both populations expressed the genes for interleukin 2 (IL-2) and its receptor, but only adult T cells were capable of transcribing mRNAs for IL-3, IL-4, IL-5, IL-6, interferon gamma, and granulocyte/macrophage colony-stimulating factor. However, neonatal T cells could be induced to undergo functional differentiation in vitro, thereby acquiring the capacity to express the lymphokine gene repertoire characteristic for adult T cells. These data suggest that the T cells generated from neonatal blood by a primary stimulation in vitro are functionally indistinguishable from the T cells in adult blood that presumably have undergone primary stimulation in vivo. Therefore, we propose that the term "memory cell" be applied to those T cells that ...
Transmembrane signaling of normal human T cells was explored with mAbs directed at TCR, CD2, CD4, CD5, or CD8 antigens and highly purified CD4+ T cells and CD8+ T cells. Our experiments explicitly show that: (a) crosslinkage of TCR with the CD2 antigen, and not independent crosslinking of TCR and of CD2 antigen or crosslinking of either protein with the CD4 or CD8 antigen induces significant proliferation independent of co-stimulatory signals (e.g., accessory cells, recombinant lymphokines, or tumor promoter), (b) F(ab)2 fragments of mAb directed at the TCR and F(ab)2 anti-CD2, crosslinked with F(ab)2 fragments of rabbit anti-mouse IgG, promote the proliferation of highly purified T cells, (c) a prompt and sustained increase in intracellular free Ca2+ concentration results from crosslinkage of TCR with the CD2 antigen, (d) T cell proliferation induced by this novel approach is curtailed by EGTA and by direct or competitive inhibitors of PKC, (e) crosslinkage of TCR with the CD2 antigen ...
References for Abcams Recombinant Human Interleukin 34 protein (ab109933). Please let us know if you have used this product in your publication
Mechanism of Action: Immune modulator. Aldesleukin (recombinant IL-2; rIL-2) is a non-glycosylated interleukin-2 (IL-2) product. It is made via recombinant DNA technology that uses an E. coli strain containing an analog of the human IL-2 gene. The biological activity of aldesleukin is similar to that of endogenous IL-2. Aldesleukin is currently FDA-approved for treating metastatic renal cell carcinoma and melanoma.3 In HIV-related clinical trials, aldesleukin is the most commonly studied IL-2 product.6. IL-2 is a type I cytokine belonging to a subfamily of cytokines that uses the common γ-chain receptor. Physiologically, IL-2 is produced in secondary lymphoid organs, primarily by CD4 cells, following activation by antigen. Once bound to the IL-2 receptor, IL-2 can activate multiple signaling pathways, including the JAK-STAT, PI3K-AKT, and MAPK pathways.2,7-9. IL-2 is a T cell growth factor that promotes T cell proliferation and survival. It stimulates the cytotoxic activity of CD8 and natural ...
IL-2 is a secreted cytokine that is important for the proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL-4) and interleukin 7 (IL-7). The expression of this gene in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling the precise expression of a single gene. The targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role of this gene in the immune response to antigenic stimuli. Recombinant Human Interleukin-2 (rHu IL-2) produced in HEK cells is a glycosylated monomer, having a total molecular weight of 15 kDa. It has been purified by proprietary chromatographic techniques ...
Over the past few years recombinant human interleukin-2 (IL-2), with or without infusion of in vitro generated lymphokine-activated killer (LAK) cells, has been administered to patients with...
Un metodo per espandere γδ cellule T dalle cellule mononucleate del sangue periferico (PBMC) è descritta. PBMC cellule derivate γδ T...
Until recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with dacarbazine (DTIC) and immunotherapy with high-dose interleukin-2 (HD IL-2) or interferon-α (IFN-α).
Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: Role in restricted conformational mobility and compaction of native state Journal Article ...
Interleukin-12 is a disulfide-linked heterodimeric protein (p70), composed of two subunits, p35 and p40, which are encoded by two different genes. Accumulating data indicate that p40 secretion precedes that of IL-12 expression. In addition to its ability to covalently bind to p35 to form IL-12, p40 can bind to p19 to form IL-23. Recombinant human IL-12 p40 is a 40 kDa protein containing 306 amino acid residues ...
NEX232 Interleukin-1 (IL-1) refers to a group of three polypeptides (interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β) and interleukin-1 receptor antagonist (IL-1Ra)), that play a central role in the regulation of immune and inflammatory responses.. IL-1β is a pro-inflammatory cytokine involved in immune defense against infection. ...
The FDA recently approved a new, more concentrated format of the high-dose bolus of the GP IIb/IIIa agent tirofiban (premixed, ready to use, at 250 mcg/mL in a 15 mL vial). Craig Walker, MD, answers questions about the use of GP IIb/IIIa agents in pe ...